.jpg "Seres Therapeutics (NASDAQ: MCRB)")
Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Seres Therapeutics (MCRB) yesterday. The company’s shares opened today at $6.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 2.2% and a 42.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, United Therapeutics, and G1 Therapeutics Inc.
Seres Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.33, a 155.5% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $15 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.32 and a one-year low of $4.42. Currently, Seres Therapeutics has an average volume of 106K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seres Therapeutics, Inc. is a microbiome therapeutics platform company, which engages in the development of biological drugs. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
